Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Venetoclax + Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Houston, Texas
This trial looks at how well two drugs work to treat patients with chronic or small lymphocytic leukemia. Venetoclax may stop cancer cell growth by blocking a protein needed for cell survival. Ibrutinib may stop cancer cell growth by blocking enzymes needed for cell growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service